Drug Profile

BSI 082

Alternative Names: BSI-082

Latest Information Update: 31 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biosion
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Phagocyte stimulants; SIRPA protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

24 Jan 2024 Biosion receives IND approval from the U.S. Food and Drug Administration (US FDA) for BSI 082 for solid tumours
12 Sep 2022 Biosion plans to file an IND application for Solid tumours in second half of 2023 (Biosion pipeline, September 2022)
08 Apr 2022 Pharmacodynamics data from a preclinical trial in cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com